

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/587,052
				Filing Date	04-09-2007
				First Named Inventor	Bunn Jr.
				Art Unit	1642
				Examiner Name	AEDER, SEAN E
Sheet	1	of	2	Attorney Docket Number	2848-65-PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	1	WO 2004/063709	07/29/04	SQUIBB BRISTOL MYERS CO		
	2	WO 2005/067667	07/28/05	SQUIBB BRISTOL MYERS CO		
	3	WO 2005/094332	10/13/05	SQUIBB BRISTOL MYERS CO		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. <sup>1</sup>	
	4	BASELGA et al., "Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients with Five Selected Solid Tumor Types" Journal of Clinical Oncology, 2002, Vol. 20, No. 21, pages 4292-4302
	5	CHINNAIYAN ET AL. "Enhancing the anti-tumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition", Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings, Vol. 22, No. 14S, 3029
	6	DEEB ET AL., "Altered E-Cadherin and Epidermal Growth Factor Receptor Expressions are Associated with Patient Survival in Lung Cancer: A Study Utilizing High-Density Tissue Microarray and Immunohistochemistry", Modern Pathology, 2004, Vol. 17, pages 430-439

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/587,052
				Filing Date	04-09-2007
				First Named Inventor	Bunn Jr.
				Art Unit	1642
				Examiner Name	AEDER, SEAN E
Sheet	2	of	2	Attorney Docket Number	2848-65-PUS

	7	WITTA ET AL., "Genes and Proteins Involved in Predicting Sensitivity/Resistance to Gefitinib in Lung Cancer", presented at the October 29, 2004 Meeting for the European Society for Medical Oncology (EMSO), 1 page
	8	International Preliminary Report on Patentability for International (PCT) Patent Application No. PCT/US2005/002325, issued July 24, 2006 (Attorney's Ref. No. 2848-65-PCT)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.